Glycemic metrics
hyperglycemia, hypoglycemia
HYPERGLYCEMIA, TYPE 1 DIABETES, HYPOGLYCEMIA
The mean TIR percentage between 3.9 and 10 mmol/L was 55.2% at the baseline and 61.3% at 12 weeks in the unblinded isCGM group, and 57.4% at the baseline and 59.7% at 12 weeks in the blinded isCGM group. The values were significantly higher in the unblinded isCGM group (P < 0.001), but were not significant in the blinded isCGM group (Glycaemic and glucose variability outcomes in a study of the efficacy of unblinded and blinded intermittently flash continuous glucose monitoring on glycemic control in adults with type 1 diabetes.Values are mean ± SD.*P<0.05 between screening visit and end visit in the unblinded isCGM group or blinded isCGM group.†P<0.05 between unblinded isCGM group and blinded isCGM group in the screening visit or end visit.The efficacy of unblinded and blinded intermittently flash continuous glucose monitoring on glycemic control in adults with type 1 diabetes. Percentage of time in range The percentage of time in which hyperglycemia occurred (>13.9 mmol/L) was 12.8% at the baseline and 8.5% during follow-up in the blinded isCGM group, and 11.4% at the baseline and 9.1% at 12 weeks in the blinded isCGM group. The mean hyperglycemia time was significantly lower in the unblinded isCGM group (P < 0.001), but the difference between the baseline and 12-week values were not significantly different in the blinded isCGM group (The CV (-2.4%), SD (-0.3 mmol/L), and MAGE (-0.7 mmol/L) were significantly lower at 12 weeks in the unblinded isCGM group (P < 0.001), but these values did not decrease significantly compared to the baseline in the blinded isCGM group (Mean HbA1c was 8.0% at the baseline and 7.5% at 12 weeks in the unblinded isCGM group, and it was 7.7% at the baseline and 7.3% at 12 weeks in the blinded isCGM group. HbA1c showed a significant reduction of 0.5% in the unblinded isCGM group and 0.4% in the blinded isCGM group (P < 0.001 for both groups) (After adjusting for between-group differences, no significant difference remained in the effect of the study treatment between the unblinded isCGM and blinded isCGM groups with regard to 12-week TIR, hypoglycemia time, hyperglycemia time, CV, SD, MAGE, and HbA1c (P > 0.05) (